3 September 2007
- HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in patients interrupting treatment in the SMART trial: new study to randomise patients with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3
- CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r
- Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
- Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
- Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study
- Penile washing directly after sex increased the risk of acquiring HIV: circumcision effective for men in high prevalence populations no protective effect in gay men
- HBV or HCV coinfection produced higher risk from treatment interruptions: drug holidays and hepatitis dont mix
- 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney
- Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?
- The growth hormone releasing factor analogue tesamorelin (TH9507) reduces visceral fat, but what else does it do?
- Does diabetes have the same impact on cardiovascular risk in HIV-positive patients as it does in the general population?
- Increased rates of pre-term delivery are associated with the Initiation of HAART during pregnancy: a single-centre cohort study